Microstructure Formation and Characterization of Long-Acting Injectable Microspheres: The Gateway to Fully Controlled Drug Release Pattern
Mengdi Wang,Shan Wang,Changhao Zhang,Ming Ma,Bohua Yan,Xinming Hu,Tianjiao Shao,Yan Piao,Lili Jin,Jing Gao
DOI: https://doi.org/10.2147/ijn.s445269
IF: 7.033
2024-02-19
International Journal of Nanomedicine
Abstract:Mengdi Wang, 1, &ast Shan Wang, 1, &ast Changhao Zhang, 2, &ast Ming Ma, 1 Bohua Yan, 1 Xinming Hu, 2 Tianjiao Shao, 2 Yan Piao, 2 Lili Jin, 2 Jing Gao 1 1 State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, People's Republic of China; 2 College of Pharmacy, Key Laboratory of Natural Medicines of the Changbai Mountain of Ministry of Education, Yanbian University, Yanji, Jilin, 133002, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jing Gao; Lili Jin, Email ; Long-acting injectable microspheres have been on the market for more than three decades, but if calculated on the brand name, only 12 products have been approved by the FDA due to numerous challenges in achieving a fully controllable drug release pattern. Recently, more and more researches on the critical factors that determine the release kinetics of microspheres shifted from evaluating the typical physicochemical properties to exploring the microstructure. The microstructure of microspheres mainly includes the spatial distribution and the dispersed state of drug, PLGA and pores, which has been considered as one of the most important characteristics of microspheres, especially when comparative characterization of the microstructure (Q3) has been recommended by the FDA for the bioequivalence assessment. This review extracted the main variables affecting the microstructure formation from microsphere formulation compositions and preparation processes and highlighted the latest advances in microstructure characterization techniques. The further understanding of the microsphere microstructure has significant reference value for the development of long-acting injectable microspheres, particularly for the development of the generic microspheres. Keywords: long-acting injectable microsphere, microstructure, PLGA, controlled drug release Graphical Long-acting injectable (LAI) microspheres have attracted considerable attention due to their unique advantages, such as reduced administration frequency, improved patient compliance, and avoidance of side effects, etc. 1–3 Following the release of the first LAI microsphere product (Lupron Depot ® ) in 1989, 4 the US Food and Drug Administration (FDA) has authorized 12 LAI microsphere products based on the poly(lactide-co-glycolide) (PLGA) polymer entirely, while no generic microspheres have been approved yet. To obtain FDA approval, a generic LAI microsphere must exhibit qualitative (Q1) and quantitative (Q2) similarity to its reference-listed drug (RLD). 5,6 However, attaining Q1/Q2 similarity alone does not guarantee consistent drug release behavior with the RLD. 7 The microstructure of microspheres mainly includes the spatial distribution and the dispersed state of drug, PLGA, and pores. 8 Its complexity mainly derives from the multi-attribute formulation compositions and multi-step manufacturing processes. 9–11 The properties and interactions of the drug, PLGA, and solvent, usually collectively dictate the impact of formulation composition on microstructure. 12,13 Besides the formulation, the crucial manufacturing processes, such as emulsification, solidification, and drying, can generate LAI microspheres with distinct release performance. 14,15 The significant impact of microstructure on LAI microsphere product release behavior has been emphasized in numerous studies. 8,16–19 The FDA also recommended Q3, the similarity of microstructure, as part of the bioequivalence assessment. Many studies have also suggested that Q1/Q2/Q3 is necessary for bioequivalence. 15,20–22 The numerous studies investigating the key factors impacting the microstructure and release behavior of LAI microspheres have primarily focused on formulation composition and preparation processes. 23–25 However, these researches have not made a substantial contribution to the development of generic LAI microspheres. On the one hand, the microstructure has not received adequate consideration in the establishment of critical quality attributes (CQAs) of microspheres. On the other hand, the absence of high-resolution, reproducible, and efficient characterization techniques hinders the comprehension of the microstructure. 26,27 Enhanced understanding will establish microstructure as a link between the formation and the release characteristics of microspheres. Conventional techniques usually characterize the structural features of LAI microspheres by determining morphology, particle size and porosity. As s -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology